Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 24, 2009

Israeli Government Boosts Compugen Drug Discovery Funding with $400K

  • The Office of the Chief Scientist (OCS) of Israel awarded Compugen a $400,000 grant to support development during 2009 of the company’s FPRL1 anti-inflammatory program and its TP program for assessing the potential of novel peptides and proteins in cancer and cardiovascular disorders.

    The new financing follows a $500,000 award, which came three weeks ago from the OCS, to support research into the discovery of new toxicity biomarkers and antibody drug targets. The grant will also be used to enhance Compugen’s predictive discovery capabilities infrastructure. 

    The company’s FPRL1 G protein-coupled receptor agonist program is evaluating the therapeutic potential of its CGEN-855 A and B peptide candidates as FPRL1 receptor agonists. The peptides are being developed under an evaluation and license option agreement with Merck Serono inked in November 2008. 



    ♦♦♦
    Related Compugen News

    Teva-Compugen Alliance Yields Biomarkers for Detection of Drug-Induced Kidney Toxicity (Mar. 24, 2009)
    Compugen Selects Nine Therapeutics to Reposition (July 31, 2007)
    Compugen and Mayo Clinic to Discover Biomarkers in Heart Disease (Apr. 30, 2007)
    Medarex and Compugen Partner on Mab-Based Therapeutics in Oncology and Autoimmune Diseases (Jan. 23, 2007)



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »